Survivin expression in glioblastomas correlates with proliferation, but not with apoptosis

Anticancer Research

Volumn 28, Issue 1 A, 2008, Pages 109-118

  Mellai, Marta ^a   Caldera, Valentina ^a   Patrucco, Alessia ^a   Annovazzi, Laura ^a   Schiffer, Davide ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Apoptosis; Glioblastoma; Mitosis; Survivin

Indexed keywords

CASPASE 3; KI 67 ANTIGEN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN BID; SURVIVIN;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MITOSIS INDEX; PRIORITY JOURNAL; PROTEIN EXPRESSION;

APOPTOSIS; CELL GROWTH PROCESSES; CELL NUCLEUS; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS;

EID: 40549127131     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nature Med 3: 917-921, 1997.
2. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T and Reed JC: IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 58: 5315-5320, 1998.
3. Shin S, Sung BJ, Cho YS, Kim HJ, Ha NC, Hwang JI, Chung CW, Jung YK and Oh BH: An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 40: 117-123, 2001.
4. Dohi T, Beltrami E, Wall NR, Plescia J and Altieri DC: Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 114: 1117-1127, 2004.
5. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC and Altieri DC: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396: 580-584, 1998.
6. Skoufias DA, Molinari C, Lacroix FB and Margolis R: Human survivin is a kinetochore-associated passenger protein. J Cell Biol 151: 1575-1582, 2000.
7. Altieri DC: Molecular circuits of apoptosis regulation and cell division control: the survivin paradigm. J Cell Biochem 92: 656-663, 2004.
8. Fortugno P, Wall NR, Giodini A, O'Connor DS, Plescia J, Padgett KM, Tognin S, Marchisio PC and Altieri DC: Survivin exists in immunohistochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci 115: 575-585, 2002.
9. Suzuki A, Hayashida M, Ito T, Kawano H, Nakano T, Miura M, Akahane N and Shiraki K: Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16(INK4a) and Cdk2/cyclin E complex activation. Oncogene 19: 3225-3234, 2000.
10. Suzuki A, Ito T, Kawano H, Hayashida M, Hayasaki Y, Tsutomi Y Akahane N, Miura M and Shiraki K: Survivin initiates procaspase3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death. Oncogene 19: 1346-1353, 2000.
11. Zhao J, Tenev T, Martins LM, Downward J and Lemoine NR: The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J Cell Sci 113: 4363-4371, 2000.
12. Mahotka C, Liebmann J, Wenzel M, Suschek CV, Schmitt M, Gabbert HE and Gerharz CD: Differential subcellular localization of functionally divergent survivin splice variants. Cell Death Diff 9: 1334-1342, 2002.
13. Kleinschmidt-DeMasters BK, Heinz D, McCarthy PJ, Bobak JB, Lillehei KO, Shroyer AL and Shroyer KR: Survivin in glioblastomas. Protein and messenger RNA expression in comparison with telomerase levels. Arch Pathol Lab Med 127: 826-833, 2003.
14. Conway EM, Zwerts F, Van Eygen V, DeVriese A, Nagai N, Luo W and Collen D: Survivin-dependent angiogenesis in ischemic brain: molecular mechanisms of hypoxia-induced up-regulation. Amer J Pathol 163: 935-946, 2003.
15. Sasaki T, Lopes MBS, Hankins GR and Heim GA: Expression of survivin, an inhibitor of apoptosis protein, in tumors of the nervous system. Acta Neuropathol 104: 105-109, 2002.
16. Kajiwara Y, Yamasaki F, Hama S, Yahara K, Yoshioka H, Sugiyama K, Arita K and Kurisu K: Expression of survivin in astrocytic tumors. Correlation with malignancy grade and prognosis. Cancer 97: 1077-1083, 2003.
17. Uematsu M, Ohsawa I, Aokage T, Nishimaki K, Matsumoto K, Takahashi H, Asoh S, Teramoto A and Ohta S: Prognostic significance of the immunohistochemical index of Survivin in glioma: a comparative study with the MIB-1 index. J Neuro-Oncol 72: 231-238, 2005.
18. Chakravarti A, Noli E, Black PMCL, Finkelstein DF, Finkelstein DM, Dyson NJ and Loeffler JS: Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol 20: 1063-1068, 2002.
19. Preusser M, Gelpi E, Matej R, Marosi C, Dieckmann K, Rössler K, Budka H and Hainfellner JA: No prognostic impact of survivin expression in glioblastoma. Acta Neuropathol 109: 534-538, 2005.
20. Das A, Tan W-L, Teo J and Smith DR: Expression of survivin in primary glioblastomas. J Cancer Res Clin Oncol 128: 302-306, 2002.
21. Schiffer D: Brain Tumor Pathology: Current Diagnostic Hotspots and Pitfalls. Dordrecht, Springer, 2006.
22. Pisarev V, Yu B, Salup R, Sherman S, Altieri DC and Gabrilovich DI: Full-length dominant-negative survivin for cancer immunotherapy. Clin Cancer Res 9: 6523-6533, 2003.
23. Schimmer AD and Dalili S: Targeting IAP family of caspase inhibitors as an emerging therapeutic strategy. Hematol 1: 215-219, 2005.
24. Pizem J, Cörf A, Zadravec-Zaletei L and Popovic M: Survivin is a negative prognostic marker in medulloblastoma. Neuropathol Appl Neurobiol 31: 422-428, 2005.
25. Yip KW, Shi W, Pintilie M, Martin JD, Mocanu JD, Wong D, MacMillan C, Gullane P, O'Sullivan B, Bastianutto C and Liu FF: Prognostic significance of the Epstein-Barr virus, p53, Bcl-2, and survivin in nasopharyngeal cancer. Clin Cancer Res 12: 5726-5732, 2006.
26. Caldas H, Jiang Y, Holloway MP, Fangusaro J, Mahotka C, Conway EM and Altura RA: Survivin splice variants regulate the balance between proliferation and cell death. Oncogene 24: 1994-2007, 2005.
27. Fangusaro JR, Jiang Y, Holloway MP, Caldas H, Singh V, Boué DR, Hayes J and Altura RA: Survivin, survivin-2B, and survivin-deItaEx3 expression in medulloblastoma: biologic markers of tumour morphology and clinical outcome. Br J Cancer 92: 359-365, 2005.
28. Grzybicki DM, Liu Y, Moore SA, Brown HG, Silverman JF, D'Amico F and Raab SS: Interobserver variability associated with the MIB-1 labeling index. High levels suggest limited prognostic usefulness for patients with primary brain tumors. Cancer 92: 2720-2726, 2001.
29. Bredel M, Piribauer M, Marosi C Birner P, Gatterbauer B, Fischer I, Ströbel T, Rössler K, Budka H and Hainfellner JA: High expression of DNA topoisomerase IIα and Ki-67 antigen is associated with prolonged survival in glioblastoma patients. Eur J Cancer 38: 1343-1347, 2002.
30. Xia F and Altieri DC: Mitosis-independent survivin gene expression in vivo and regulation by p53. Cancer Res 66: 3392-3395, 2006.
31. Mellai M and Schiffer D: Apoptosis in brain tumors: prognostic and therapeutic considerations. Anticancer Res 27: 437-448, 2007.
32. Scaffidi C, Schmitz I, Zha J, Korsmeyer SJ, Krammer PH and Peter ME: Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. J Biol Chem 274: 22532-22538, 1999.
33. Ashley DM, Riffkin CD, Muscat AM, Knight MJ, Kaye AH, Novak U and Hawkins CJ: Caspase 8 is absent or low in many ex vivo gliomas. Cancer 104: 1487-1496, 2005.
34. cdc2 phosphorylation of survivin. PNAS USA 97: 13103-13107, 2000.
35. Altieri DC: The case of survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol 18: 609-615, 2006.
36. Vagnarelli P and Earshaw WC: Chromosomal passengers: four-dimensional regulation of mitotic events. Chromosoma 113: 211-222, 2004.
37. Hao Y, Sekine K, Kawabata A, Nakamura H, Ishioka T, Ohata H, Katayama R, Hashimoto C, Zhang X, Noda T, Tsuruo T and Naito M: Apollon ubiquitinates SMAC and caspase-9, and has an essential cytoprotective function. Nature Cell Biol 6: 849-860, 2004.
38. Schiffer D, Fiano V, Chiadó-Piat L, Mortara P, Richiardi P and Cavalla P: Distribution of activated caspase-3 in relation with apoptosis in human malignant gliomas. Neurosci Lett 300: 37-40, 2001.
39. Mizoguchi M, Betensky R, Batchelor TT, Bernay DC, Davide DN and Nutt CL: Activation of STATr, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival. J Neuropathol Exp Neurol 65: 1181-1188, 2006.
40. Perabo FG, Frössler C, Landwehrs G, Schmidt DH, von Rücker A, Wirger A and Müller SC: Indirubin-3′-monoxime, a CDK inhibitor induces growth inhibition and apoptosis-independent up-regulation of survivin in transitional cell cancer. Anticancer Res 26: 2129-2136, 2006.